EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Irritable Bowel Syndrome - Pipeline Review, H1 2015

  • ID: 3330559
  • Report
  • June 2015
  • 123 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actavis Plc
  • Ardelyx, Inc.
  • Dong-A Socio Group
  • ImmusanT, Inc.
  • RaQualia Pharma Inc.
  • Synthetic Biologics, Inc.
  • MORE
Irritable Bowel Syndrome - Pipeline Review, H1 2015

Summary

This, ‘Irritable Bowel Syndrome - Pipeline Review, H1 2015’, provides an overview of the Irritable Bowel Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actavis Plc
  • Ardelyx, Inc.
  • Dong-A Socio Group
  • ImmusanT, Inc.
  • RaQualia Pharma Inc.
  • Synthetic Biologics, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Irritable Bowel Syndrome Overview
Therapeutics Development
Pipeline Products for Irritable Bowel Syndrome - Overview
Pipeline Products for Irritable Bowel Syndrome - Comparative Analysis
Irritable Bowel Syndrome - Therapeutics under Development by Companies
Irritable Bowel Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Irritable Bowel Syndrome - Products under Development by Companies
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Actavis Plc
Alba Therapeutics Corporation
Alfa Wassermann S.p.A
Ardelyx, Inc.
Astellas Pharma Inc.
Dong-A Socio Group
GIcare Pharma Inc
Hanmi Pharmaceuticals, Co. Ltd.
ImmusanT, Inc.
Ironwood Pharmaceuticals, Inc.
Juno Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Protagonist Therapeutics Inc.
RaQualia Pharma Inc.
SK Biopharmaceuticals Co., Ltd.
SK Chemicals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Takeda Pharmaceutical Company Limited
Yuhan Corporation
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(Bacillus subtilis + mosapride + Streptococcus faecium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-1017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-7147 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Blautix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eluxadoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GIC-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibodutant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Antagonize M3 for Irritable Bowel Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-2952 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00202730 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00310941 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SKI-3246 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-480 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irritable Bowel Syndrome - Recent Pipeline Updates
Irritable Bowel Syndrome - Dormant Projects
Irritable Bowel Syndrome - Discontinued Products
Irritable Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
May 27, 2015: Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea in Adults
May 20, 2015: 4D pharma Provides Research Update on Clinical Development Of Blautix
May 19, 2015: Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
May 18, 2015: Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week Poster
Feb 17, 2015: Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week 2015
Jan 05, 2015: 4D pharma Provides Research Update
Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation
Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H1 2015
Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
Irritable Bowel Syndrome - Pipeline by Actavis Plc, H1 2015
Irritable Bowel Syndrome - Pipeline by Alba Therapeutics Corporation, H1 2015
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H1 2015
Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Dong-A Socio Group, H1 2015
Irritable Bowel Syndrome - Pipeline by GIcare Pharma Inc, H1 2015
Irritable Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Irritable Bowel Syndrome - Pipeline by ImmusanT, Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Juno Therapeutics Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Irritable Bowel Syndrome - Pipeline by SK Chemicals Co., Ltd., H1 2015
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H1 2015
Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Irritable Bowel Syndrome - Pipeline by Yuhan Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
Irritable Bowel Syndrome - Dormant Projects, H1 2015
Irritable Bowel Syndrome - Dormant Projects (Contd..1), H1 2015
Irritable Bowel Syndrome - Dormant Projects (Contd..2), H1 2015
Irritable Bowel Syndrome - Dormant Projects (Contd..3), H1 2015
Irritable Bowel Syndrome - Discontinued Products, H1 2015
Irritable Bowel Syndrome - Discontinued Products (Contd..1), H1 2015

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H1 2015
Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
A. Menarini Industrie Farmaceutiche Riunite Srl
Actavis Plc
Alba Therapeutics Corporation
Alfa Wassermann S.p.A
Ardelyx, Inc.
Astellas Pharma Inc.
Dong-A Socio Group
GIcare Pharma Inc
Hanmi Pharmaceuticals, Co. Ltd.
ImmusanT, Inc.
Ironwood Pharmaceuticals, Inc.
Juno Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Protagonist Therapeutics Inc.
RaQualia Pharma Inc.
SK Biopharmaceuticals Co., Ltd.
SK Chemicals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Takeda Pharmaceutical Company Limited
Yuhan Corporation
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll